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Abstract
Background: Previous studies of the prognostic importance of FOXO1 fusion status 
in patients with rhabdomyosarcoma (RMS) have had conflicting results. We re‐ex-
amined risk stratification by adding FOXO1 status to traditional clinical prognostic 
factors in children with localized or metastatic RMS.
Methods: Data from six COG clinical trials (D9602, D9802, D9803, ARST0331, 
ARTS0431, ARST0531; two studies each for low‐, intermediate‐ and high‐risk pa-
tients) accruing previously untreated patients with RMS from 1997 to 2013 yielded 
1727 evaluable patients. Survival tree regression for event‐free survival (EFS) 
was conducted to recursively select prognostic factors for branching and split. 
Factors included were age, FOXO1, clinical group, histology, nodal status, num-
ber of  metastatic sites, primary site, sex, tumor size, and presence of metastases in  
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1 |  INTRODUCTION
Rhabdomyosarcomas (RMS) constitute 40% of soft tissue 
sarcomas in children, with an incidence of 4.5 cases per mil-
lion children and adolescents per year.1 Risk stratification to 
guide therapy intensity traditionally includes clinical factors 
present at diagnosis. Analysis of patient and disease char-
acteristics of patients with nonmetastatic RMS treated on 
the third and fourth Intergroup Rhabdomyosarcoma Studies 
(IRS‐III and IRS‐IV) identified prognostic significance of 
histology, stage, clinical group, and primary site. Subsequent 
clinical studies from 1997 to 2004 divided patients into two 
low‐risk, one intermediate‐risk, and one high‐risk prognostic 
subgroups for treatment assignment.2 Oberlin and colleagues 
performed a multivariate analysis of risk factors in 788 pa-
tients with metastatic RMS treated in nine studies performed 
by European and American cooperative groups from 1984 to 
2000.3 Inferior event‐free survival (EFS) was correlated with 
age under 1 year or older than 10 years, unfavorable site of 
primary tumor (defined as extremity and “other” sites), pres-
ence of three or more sites of metastatic disease, and pres-
ence of bone or bone marrow involvement; histology was not 
independently associated with outcome.
Cytogenetic studies identify a frequent t(2;13)(q35;q14) 
or variant t(1;13)(p36;q14) chromosomal translocation in 
most cases of alveolar RMS (ARMS). These translocations 
involve the PAX3 gene on chromosome 2 or the PAX7 gene 
on chromosome 1 and the FOXO1 gene on chromosome 13 to 
generate PAX3‐FOXO1 or PAX7‐FOXO1 fusion genes, which 
encode fusion proteins with oncogenic activity. Molecular 
pathologic analysis of fusion status revealed that 80% of 
ARMS cases contain a FOXO1 fusion (60% with PAX3‐
FOXO1 fusion and 20% with PAX7‐FOXO1 fusion) whereas 
the vast majority (>95%) of embryonal RMS (ERMS) cases 
do not contain any FOXO1 fusion.4
Two retrospective studies on patients treated on multiple 
different clinical trials spanning two decades have shown 
conflicting results on the prognostic significance of FOXO1 
fusion status. Williamson et al found that fusion‐positive pa-
tients have an inferior outcome compared to fusion‐negative 
patients, whereas Stegmaier et al showed no association be-
tween outcome and fusion status in patients with ARMS.5,6 
Analyses of patients with low‐ (n  =  16) and intermediate‐
risk (n = 434) RMS treated on a series of recent Children's 
Oncology Group (COG) trials confirmed the prognostic sig-
nificance of FOXO1 fusion status.7,8
The purpose of the current study was to determine if the 
childhood RMS risk stratification algorithm could be further 
strengthened with the addition of FOXO1 fusion status to tra-
ditional clinical features in a cohort of nearly 2000 patients 
from the six most recent COG clinical trials. We performed 
statistical modeling incorporating known risk factors, includ-
ing FOXO1 fusion status, to determine which risk factors 
were most important in determining outcomes. Based on the 
results of this modeling, we propose new risk group defini-
tions that more accurately segregate patients into meaning-
ful prognostic subgroups than the previous risk stratification 
system.
2 |  MATERIALS AND METHODS
Patients with newly diagnosed RMS enrolled on six previ-
ously reported COG studies, shown in Table 1, conducted 
from 1997 to 2013 were included in this analysis.9-14 These 
trials were approved by the institutional review boards of 
bone/bone marrow, soft tissue, effusions, lung, distant lymph nodes, and other sites. 
Definition and outcome of the proposed risk groups were compared to existing sys-
tems and cross‐validated results.
Results: The 5‐year EFS and overall survival (OS) for evaluable patients were 69% 
and 79%, respectively. Extent of disease (localized versus metastatic) was the first 
split (EFS 73% vs 30%; OS 84% vs. 42%). FOXO1 status (positive vs negative) was 
significant in the second split both for localized (EFS 52% vs 78%; OS 65% vs 88%) 
and metastatic disease (EFS 6% vs 46%; OS 19% vs 58%).
Conclusions: After metastatic status, FOXO1 status is the most important prognostic 
factor in patients with RMS and improves risk stratification of patients with localized 
RMS. Our findings support incorporation of FOXO1 status in risk stratified clinical 
trials.
K E Y W O R D S
fusion status, rhabdomyosarcoma, risk stratification, survival tree regression
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each participating institution or Pediatric Central Review 
Board, as required. Informed consent/assent from the patient 
and/or parent/guardian as appropriate was obtained before 
enrollment.
Prognostic factors incorporated in the model include age 
at diagnosis (categorized based on previous studies into <1, 
1 to 9, 10+ years),15 sex, primary site (favorable (orbit, head 
and neck (excluding parameningeal), genitourinary (exclud-
ing bladder/prostate), and biliary tract/liver) versus unfavor-
able (bladder/prostrate, extremity, cranial parameningeal, 
other (includes trunk, retroperitoneum, pelvis, perineal/peri-
anal, intrathoracic, gastrointestinal)), tumor size (≤5  cm, 
>5 cm), histology (ARMS, ERMS), FOXO1 fusion status 
(positive, negative), clinical group (I, II, III, IV),16 nodal 
status (N0, nodal involvement absent; N1, nodal involvement 
present), number of metastatic sites (ranging from 0 to 6), 
and presence or absence of metastasis in the following sites: 
bone or bone marrow as a single variable, distant soft tissue, 
pleural effusion, lung, distant lymph nodes, and other sites. 
Tumor invasiveness was not included as it is not used in 
current risk stratification. Stage was not included because 
all elements of stage (primary site, tumor size, regional 
nodal status, and presence of metastases) were individually 
included in the analysis. Only patients with complete data 
were eligible for analyses. Since virtually all ERMS are 
fusion‐negative, the 1270 ERMS patients without FOXO1 
fusion data were assumed to be fusion‐negative.17-19 Within 
our study population, only 1 of the 58 (1.7%) ERMS patient 
with known fusion data were fusion‐positive. When central-
ized FOXO1 fusion testing (using previously reported re-
verse transcription—polymerase chain reaction (RT‐PCR)20 
or fluorescence in situ hybridization (FISH)21 and method-
ology was not available, institutional assessment was used 
(n = 51 patients). Patients with histology other than ARMS, 
ERMS, botryoid or spindle cell/sclerosing RMS (n = 128) 
and those with missing clinical data (n  =  353) were also 
excluded yielding 1727 evaluable patients.
Event‐free survival was the primary endpoint and was cal-
culated from date of study enrollment to date of first event, 
which included tumor recurrence or progression, secondary 
malignancy, and death due to any cause, or date of last con-
tact for those without events. EFS was selected as the primary 
endpoint for this analysis as the risk stratification system 
should be designed to evaluate outcomes of upfront therapy. 
In addition, overall survival (OS) provides fewer events than 
EFS, resulting in lower power to stratify subsets of patients.
We conducted survival tree regression for EFS to de-
termine the prognostic impact of the risk factors discussed 
T A B L E  1  Risk group assignment by risk group definition
Risk group assignment
Risk group stratification definition
D‐series (1997‐2004) ARST‐series (2004‐2013)
Low D9602 (NCT00002995): (ERMS only)
Subset A:
Fav site, any size, Stage 1, Group I and II, N0;
Fav site, any size, Stage 1, Group III, N0, (orbit only);
Unfav site, ≤ 5cm, Stage 2, Group I, N0, Nx;
Therapy: VA x 45 wk
Subset B:
Fav site, any size, Stage 1, Group II, N1;
Fav site, any size, Stage 1, Group III, N1 (orbit only);
Fav site (except orbit), any size, Stage 1, Group III, N0, N1;
Unfav site, ≤5 cm, Stage 2, Group II, N0, Nx;
Unfav site, ≤5 cm with N1 or >5 cm any size, Stage 3, 
Group I/II, N0, Nx, N1
Therapy similar to D9803
ARST0331 (NCT00075582): (ERMS only)
Subset 1:
Stage 1, Group I and II, N0;
Stage 1, Group III, N0, Nx, (orbit only);
Stage 2, Group I, N0, Nx, and Group II;
Therapy: VAc x 4, VA x4
Subset 2:
Stage 1, Group III, N0, Nx, (non‐orbital);
Stage 3, Group I/II
Therapy VAc x 4, VA x 12
Intermediate D9803 (NCT00003958)
Stage 1‐3, Group I‐III, ARMS;
Stage 2/3, Group III, ERMS;
Stage 4, Group IV, ERMS, <10 years
Therapy: VAC vs VAC/VTC
ARST0531 (NCT00354835)
Stage 2/3, Group III, ERMS;
Stage 1‐3, Group I‐III, ARMS
Therapy: VAc vs VAc/VI
High D9802 (NCT00003955)
Stage 4, Group IV, except ERMS <10 y
Therapy: I ± V; VAC
ARST0431 (NCT00354744)
Stage 4, Group IV
Therapy: VDc/IE/I/VAc
Abbreviations: ARMS, alveolar rhabdomyosarcoma; ERMS, embryonal rhabdomyosarcoma; Fav, favorable; I, irinotecan; N0, No regional nodal involvement; N1, 
regional nodal involvement; Nx, nodal involvement unknown; Unfav, unfavorable; V, vincristine; VA, vincristine/actinomycin; VAc, vincristine, actinomycin/cyclo-
phosphamide (dose 1.2 gm/m2); VAC, vincristine, actinomycin/cyclophosphamide (dose 2.2 gm/m2); VDc, vincristine/doxorubicin/cyclophosphamide; IE, Ifosfamide/
etoposide; VTC, vincristine, topotecan, cyclophosphamide.
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above using the R package “partykit” to produce a survival 
tree.22 We selected this method as it reduces variable se-
lection bias towards variables with more than a single cut 
point. In addition, this method reduces over‐fitting by im-
plementing a statistically motivated stopping criterion. The 
model stops splitting when there is no longer a statistically 
significant split and this eliminates the need for pruning. 
Recursively, the factor most strongly associated with the EFS 
in the univariate fashion was selected for branching and split 
using a goodness of split measure that optimizes between‐
node separation using the log‐rank statistics.23,24 This pro-
cess continues until no statistically significant associations 
exist. The algorithm utilizes the log‐rank score at a 5% sig-
nificance level and the Bonferroni method to adjust for mul-
tiple testing at each split. The 5‐year EFS and OS rates for 
each leaf in the EFS survival tree were estimated using the 
Kaplan‐Meier method.24 Confidence intervals for estimates 
of time‐to‐event distributions were calculated using Peto and 
Peto's formula.25
Once results of the survival tree were known, we used EFS 
from terminal leaves to revise the low‐, intermediate‐ and 
high‐risk definitions. Risk group assignment was arbitrary, 
but was based on cut‐offs previously derived from an analysis 
of patients with non‐metastatic disease enrolled on IRS‐III 
and IRS‐IV.2 Low risk was defined as having a 5‐year EFS of 
≥90%. Intermediate risk was defined as having a 5‐year EFS 
of ≥40% to <90%. High risk was defined as having a 5‐year 
EFS of <40%. Cross‐validation (10‐fold) was utilized for 
internal validation.26 Concordance was calculated to assess 
consistency of cross‐validated risk groups with the revised 
risk groups from the survival tree for all evaluable patients.27 
Risk stratifications utilized on the D‐series and ARST‐series 
studies (Table 1) were applied to the entire analytic cohort. 
This analysis allows for comparison of risk assignment and 
performance characteristics of risk groups based on the dif-
ferent risk stratification definitions. EFS curves were com-
pared using the log‐rank test for each risk group stratification 
definition.28
3 |  RESULTS
Table 2 shows characteristics for 2028 eligible patients. The 
estimated 5‐year EFS and OS rates for all 1727 evaluable 
patients with complete data were 69% (95% CI: 66%‐71%) 
and 79% (95% CI: 77%‐82%), respectively. The most signifi-
cant risk factor in relation to EFS resulting was clinical group 
(Figure 1). The 5‐year EFS and OS for patients with localized 
disease (Group I, II, and III) were 73% and 84% compared to 
30% and 42% for patients with metastatic disease (Group IV) 
(Figure 1; Table 3).
Among patients with localized disease, FOXO1 fusion 
status was the strongest prognostic factor. The model did not 
discriminate any further risk factors among the fusion‐posi-
tive patients after fusion status. Fusion‐negative patients had 
a 5‐year EFS of 78% and 5‐year OS of 88%. Fusion‐positive 
patients had a 5‐year EFS of 52% and OS of 65%.
Among 1285 fusion‐negative patients, primary site 
(favorable versus unfavorable) was the strongest prognos-
tic factor. Patients with favorable sites had a 5‐year EFS 
of 85% and 5‐year OS of 95% and patients with unfavor-
able sites had a 5‐year EFS of 70% and 5‐year OS of 80%. 
Within the favorable site cohort, patients in Group I had 
better outcomes than patients in Group II and III (5‐year 
EFS: 91% vs 81%; 5‐year OS: 99% vs 93%). For FOXO1 
fusion‐negative patients with Group II and III tumors in 
favorable sites, those older than 1 year had better outcome 
than those less than 1 year (5‐year EFS: 82% vs 47%; 5‐
year OS: 93% vs 80%).
For FOXO1 fusion‐negative patients with unfavorable 
sites, tumor size was the strongest prognostic factor. Patients 
with small tumors (≤5 cm) had a 5‐year EFS of 77% and 5‐
year OS of 85% and patients with large tumors (>5 cm) had 
a 5‐year EFS of 65% and 5‐year OS of 76%. For patients with 
large tumors, those 1‐10 years old had better outcome than 
those under 1 year or over 10 years (5‐year EFS: 71% vs 47%; 
5‐year OS: 81% vs 61%).
For patients with metastatic disease, FOXO1 fusion status 
was the strongest prognostic variable. Similar to patients with 
localized and fusion‐positive disease, no clinical factor fur-
ther subdivided outcome among patients with metastatic and 
fusion‐positive disease. Fusion‐negative patients had a 5‐year 
EFS of 46% and 5‐year OS of 58%, whereas fusion‐positive 
patients had a 5‐year EFS of 6% and 5‐year OS of 19%. For 
the 111 fusion‐negative patients, the number of metastatic 
sites was the strongest prognostic factor. Those with a single 
metastatic site had better outcomes than those with more than 
1 metastatic site (5‐year EFS: 54% vs 34%; 5‐year OS: 70% 
vs 40%).
Based on EFS cut points from the survival tree, we 
propose new risk groups definitions. Our revised risk defi-
nitions include a small, but well defined low‐risk group 
with excellent outcome, a much larger intermediate‐risk 
group with a wider range of outcomes, and another small, 
but well‐defined high‐risk group. We set the boundary for 
low‐risk at a 5‐year EFS of 90% or greater which included 
patients with clinical group I, favorable site, and FOXO1 
fusion‐negative tumors. The boundaries for intermedi-
ate‐risk were 5‐year EFS greater than 40% and less than 
90% and included patients with clinical group II and III, 
favorable site, FOXO1 fusion‐negative; clinical group I‐III 
FOXO1 fusion‐negative tumors in an unfavorable site; clin-
ical group I‐III, FOXO1 fusion‐positive tumors; and clin-
ical group IV, FOXO1 fusion‐negative tumors involving 
only one metastatic site. A 5‐year EFS of less than 40% 
marked the boundary for high‐risk which included patients 
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T A B L E  2  Patient and clinical characteristics
Characteristic No. of eligible patients % No. of evaluable patients %
Total No. 2028   1727  
Study
D9602 403 20 372 22
D9802 111 5 60 2
D9803 616 30 477 28
ARST0331 341 17 319 18
ARST0431 109 5 86 5
ARST0531 448 22 413 24
Age, y
<1 100 5 83 5
1‐9 1241 61 1091 63
≥10 687 34 553 32
Sex
Male 1233 61 1050 61
Female 795 39 677 39
Clinical group
I 333 16 293 17
II 343 17 304 18
III 1081 53 943 55
IV 268 13 187 11
Missing 3 0    
Histology
Alveolar 572 28 434 25
Embryonal 1328 65 1293 75
Missing 128 6    
Tumor size, cm
≤5 1077 53 948 55
>5 912 45 779 45
Missing 39 2    
Regional lymph node status
N0 1625 80 1416 82
N1 379 19 311 18
Missing 24 1    
Primary site
Favorable 832 41 735 43
Unfavorable 1193 59 992 57
Missing 3 0    
Bone/bone marrow metastases  
No 1900 94 1648 95
Yes 127 6 79 5
Missing 1 0    
Lung metastases
No 1912 94 1643 95
Yes 84 6 84 5
(Continues)
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with clinical group IV and FOXO1 fusion‐positive and 
those group IV, FOXO1 fusion‐negative with more than one 
metastatic site. Table 4 presents the percentage of patients 
and outcomes for the analytic cohort based on the D‐series, 
ARST‐series, and proposed risk group, and cross‐validated 
definitions. Concordance between cross‐validated risk 
groups and proposed risk groups was 1598/1727 = 92.3%.
Our proposed risk stratification of low‐, intermediate‐ 
and high‐risk changed the percentages of patients in each 
category. A higher percentage of patients were assigned 
to low‐risk by D‐series and ARST‐series definitions than 
by the proposed risk stratification. The 5‐year EFS for 
patients in the proposed stratification for low‐risk (91%) 
was higher than those in the D‐series (84%) and ARST‐se-
ries (84%). A lower percentage of patients in past studies 
were assigned to intermediate‐risk than by the proposed 
stratification. The 5‐year EFS for patients in the proposed 
stratification for intermediate‐risk (69%) was higher than 
those in the D‐series (63%) and ARST‐series (64%). The 
percentage of high‐risk patients in the proposed stratifica-
tion was similar to that of the D‐series and lower than the 
ARST‐series. The 5‐year EFS for high‐risk patients in the 
proposed stratification (16%) is lower than those in the D‐
series (18%) and ARST‐series (30%). Kaplan‐Meier plots 
for the three risk stratification definitions are presented in 
Figure 2A‐C.
Characteristic No. of eligible patients % No. of evaluable patients %
Missing 3 0    
Distant node metastases  
No 1939 96 1673 97
Yes 85 4 54 3
Missing 4 0    
Distant soft tissue metastases
No 1969 97 1685 98
Yes 57 2 42 2
Missing 2 0    
Pleural effusion
No 1987 98 1703 99
Yes 40 2 24 1
Missing 1 0    
Other sites metastases
No 1918 95 1653 96
Yes 109 5 74 4
Missing 1 0    
Number of metastatic sites
0 1751 86 1531 89
1 131 6 98 6
2 70 3 56 3
3 48 2 26 2
4 17 1 12 1
5 6 0 3 0
6 1 0 1 0
Missing 1 0    
FOXO1 fusion statusa
Fusion‐negativeb 1445 71 1396 81
Fusion‐positive 351 17 331 19
Missing 232 11    
Abbreviations: N0, No regional nodal involvement; N1, Regional nodal involvement.
aFOXO1 fusion data sources included centralized testing and institutional reports of reverse transcription polymerase chain reaction, fluorescence in situ hybridization, 
or cytogenetics. 
bERMS patients with missing fusion status assumed Fusion‐negative. 
T A B L E  2  (Continued)
   | 6443HIBBITTS eT al
4 |  DISCUSSION
In this large cohort of contemporarily treated patients with 
RMS, incorporating FOXO1 fusion status into the risk strati-
fication algorithm separated out a small group of patients 
with an excellent 5‐year EFS of 91%, characterized by favora-
ble site, FOXO1 fusion‐negative status, and clinical group I 
disease. These patients all received either two drug therapy 
with VA for 45  weeks or three drug therapy with 4 cycles 
of VAC and four cycles of VA. The excellent outcome and 
small number of patients in this group (14% of the patients 
analyzed) will make future studies to further refine therapy 
challenging.
We separated the remaining patients into two groups: an 
expanded intermediate‐risk group with a 5 year EFS ranging 
from 47% to 82%, (79% of the total patients analyzed) and 
a high‐risk group with a 5 year EFS of 6%‐34% (7% of the 
patients analyzed). Table 4 shows the characteristics of the 
newly defined risk groups based on this analysis.
Although the range of 5‐year EFS is large in the intermedi-
ate‐risk group, these patients would lend themselves to future 
prospective study of therapeutic strategies and molecular fea-
tures associated with outcome. For example, MG5, a 5 gene 
metagene signature is strongly associated with outcome in 
two separate cohorts of FOXO1 fusion‐negative patients with 
RMS.29,30 In an analysis of D9803 intermediate‐risk patients, 
low MG5 score had an EFS similar to the low‐risk patients de-
scribed above.29 If the prognostic value of the MG5 score can 
be confirmed in a larger prospective study which also includes 
fusion‐positive patients, it could be used to identify additional 
patients warranting less intensive therapy. Although patients 
with low MG5 scores had an excellent outcome, those treated 
on D9803 received intensive 3‐4 drug therapy. If these patients 
could be identified prospectively, they could be targeted for 
therapy reduction. Similarly, patients with a high MG5 score 
had a very poor outcome similar to the FOXO1 fusion‐posi-
tive patients, and could be targeted for novel approaches used 
for patients with metastatic disease.
Our model identified a more favorable subset of patients 
with metastatic disease: FOXO1 fusion‐negative patients 
with only one site of metastasis, similar to the clinical find-
ings of Oberlin et al.3 In this more favorable subset, 48 of 66 
patients were under 10 years at diagnosis. Modifications to 
the risk stratification algorithm moved young patients with 
metastatic ERMS from intermediate‐risk on the D‐series 
of studies to high‐risk on the ARST‐series of studies. In 
contrast to an earlier analysis of a larger cohort of patients 
with metastatic RMS that did not include FOXO1 fusion 
status and found that age 10  years and greater predicted 
a less favorable outcome, our analysis only identified the 
presence of more than one metastatic site as a predictor of 
worse outcome (and only for FOXO1 fusion‐negative tu-
mors).3 In an analysis of fusion status and outcome on two 
high‐risk RMS studies (D9802 and ARST0431), Rudzinski 
et al found Oberlin score to be more prognostic than fusion 
status but did not include metastatic patients from D9803.31 
F I G U R E  1  Event‐free survival (EFS) tree of analytic cohort with terminal leaves labeled by risk groups. EFS, event‐free survival; Fusion, 
FOXO1 fusion status
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F I G U R E  2  EFS curves by risk 
group as defined by (A) D‐series criteria; 
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Although the high‐risk group proposed here comprises few 
patients, their poor outcome (EFS 6%‐34%) lends itself to 
higher risk investigational studies to identify more effective 
therapies.
With the new risk stratification algorithm using this sur-
vival tree, the low‐ and high‐risk groups become smaller, 
and the intermediate‐risk group expands. The EFS dividing 
line between risk groups is arbitrary, but is intended to allow 
modulation of treatment intensity within clinical trials based 
upon the risk of disease recurrence. The intermediate risk 
and high risk group outcomes are still unsatisfactory, and 
justify exploration of innovative new therapeutic approaches 
with the goals to improve outcomes and define new treatment 
alternatives.
There are several differences between our analysis and 
that used previously to define IRS/COG risk stratification in 
localized RMS, limiting comparability of the two analyses.2 
The prior IRS/COG analysis did not have FOXO1 fusion sta-
tus available to include in the model, and excluded patients 
with metastatic disease and included patients with undiffer-
entiated sarcoma, whereas we did the reverse.
One potential limitation in our analysis was that patients 
with ERMS were assumed to be FOXO1 fusion‐negative for 
analytic purposes as few had undergone FOXO1 fusion test-
ing. Since cases classified as ERMS by expert central pathol-
ogy review are rarely FOXO1 fusion‐positive, FOXO1 fusion 
testing likely would not have altered the stratification of these 
patients.17-19 Other potential flaws in our study design include 
the use of both RT‐PCR and FISH for FOXO1 fusion detec-
tion and incorporation of institutional FOXO1 fusion assess-
ment when centralized testing was not available. In addition, 
the much rarer fusions in rhabdomyosarcoma (such as PAX‐
NCOA, which are not detectable by FOXO1 FISH or PCR 
studies) were not looked for, and it is not known at this time 
how they affect outcome.32 In addition, we only considered 
pretreatment factors and not therapy received. Moreover, be-
cause none of the randomized studies showed any difference 
between treatment regimens, treatment was not considered as 
an independent variable.
In conclusion, after metastatic status, FOXO1 fusion sta-
tus is the most important prognostic factor in patients with 
RMS. The current COG intermediate‐risk study, ARST1431, 
allocates treatment based on FOXO1 fusion testing. Since 
prognosis depends in part on treatment, our results are only 
applicable to patients treated on COG studies until they have 
been confirmed using an independent data set, for example 
from patients treated on the European Paediatric Soft Tissue 
Sarcoma RMS 2005 study with a different chemotherapy 
backbone and local control philosophy. The current effort to 
create an international dataset of childhood soft tissue sarco-
mas through combined efforts of a number of international 
cooperative groups may make further analyses to confirm 
these results feasible.
CONFLICT OF INTEREST
None: Dasgupta, Chi, Meyer, Rudzinski, Hibbitts, 
Rodeberg, Skapek, Spunt. Positive disclosures: Arndt 
‐‐ stock ownership Pfizer and Merck; Bradley‐‐ hono-
raria and travel funding from Ion Beam applications; 
Hawkins‐‐ travel funding from Bayer, BMS, loxo oncol-
ogy, Celgene; Barr‐‐ stock ownership by self or immediate 
family member in Abbott Labs, General Electric, Danaher 
corp, Abbvie inc, Baxter international, Celgene, Colgate 
Palmolive, Edwards lifesciences, Eli Lilly, Johnson and 
Johnson; Wolden—travel expenses from IBA and consult-
ing role in Y‐mAbs.
AUTHOR CONTRIBUTIONS
All authors have contributed toward the article in the fol-
lowing ways: (a) substantial contributions to the concep-
tion and design or analysis and interpretation of the data; 
(b) drafting the article or revising it critically for important 
intellectual content; (c) final approval of the version to be 
published; and (d) agreement to be accountable for all as-
pects of the work.
Precis: The importance of FOXO1 fusion status in risk 
stratification for treatment assignment in patients with rhab-
domyosarcoma (RMS) has been controversial. Survival tree 
regression was conducted in a group of 1727 RMS patients 
treated on 6 clinical trials to recursively select prognostic fac-
tors with the greatest impact on event‐free survival (EFS), 
and demonstrated that after metastatic status, FOXO1 fusion 
status is the most important prognostic factor in childhood 
RMS.
ORCID
Emily Hibbitts   https://orcid.org/0000-0002-2400-5469 
Sheri L. Spunt   https://orcid.org/0000-0002-1669-2676 
REFERENCES
 1. Ognjanovic S, Linabery AM, Charbonneau B, Ross JA. Trends in 
childhood rhabdomyosarcoma incidence and survival in the United 
States, 1975–2005. Cancer. 2009;115(18):4218‐4226. https ://doi.
org/10.1002/cncr.24465 
 2. Meza JL, Anderson J, Pappo AS, Meyer WH. Analysis of prog-
nostic factors in patients with nonmetastatic rhabdomyosarcoma 
treated on intergroup rhabdomyosarcoma studies III and IV: the 
Children's Oncology Group. J Clin Oncol. 2006;24(24):3844‐3851. 
https ://doi.org/10.1200/JCO.2005.05.3801
 3. Oberlin O, Rey A, Lyden E, et al. Prognostic factors in met-
astatic rhabdomyosarcomas: results of a pooled analy-
sis from United States and European Cooperative Groups. J 
Clin Oncol. 2008;26(14):2384‐2389. https ://doi.org/10.1200/
JCO.2007.14.7207
   | 6447HIBBITTS eT al
 4. Parham DM, Barr FG. Classification of rhabdomyosarcoma and its 
molecular basis. Adv Anat Pathol. 2013;20(6):387‐397. https ://doi.
org/10.1097/PAP.0b013 e3182 a92d0d
 5. Williamson D, Missiaglia E, De Reyniès A, et al. Fusion gene‐
negative alveolar rhabdomyosarcoma is clinically and molecu-
larly indistinguishable from embryonal rhabdomyosarcoma. J 
Clin Oncol. 2010;28(13):2151‐2158. https ://doi.org/10.1200/
JCO.2009.26.3814
 6. Stegmaier S, Poremba C, Schaefer KL, et al. Prognostic value of 
PAX‐FKHR fusion status in alveolar rhabdomyosarcoma: a re-
port from the cooperative soft tissue sarcoma study group (CWS). 
Pediatr Blood Cancer. 2011;57:406‐414. https ://doi.org/10.1002/
pbc.22958 
 7. Arnold MA, Anderson JR, Gastier‐Foster JM, et al. Histology, 
fusion status, and outcome in alveolar rhabdomyosarcoma with 
low‐risk clinical features: a report from the Children's Oncology 
Group. Pediatr Blood Cancer. 2016;63(4):634–639. https ://doi.
org/10.1002/pbc.25862 .
 8. Skapek SX, Anderson J, Barr FG, et al. PAX‐FOXO1 fusion sta-
tus drives unfavorable outcome for children with rhabdomyosar-
coma: a Children's Oncology Group report. Pediatr Blood Cancer. 
2013;60(9):1411‐1417. https ://doi.org/10.1002/pbc.24532 .
 9. Raney RB, Walterhouse DO, Meza JL, et al. Results of the inter-
group rhabdomyosarcoma study group D9602 protocol, using vin-
cristine and dactinomycin with or without cyclophosphamide and 
radiation therapy, for newly diagnosed patients with low‐risk em-
bryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma 
Committee of the Children's Oncology Group. J Clin Oncol. 
2011;29:1312‐1318. https ://doi.org/10.1200/JCO.2010.30.4469
 10. Arndt C, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and 
cyclophosphamide compared with vincristine, actinomycin, and cy-
clophosphamide alternating with vincristine, topotecan, and cyclo-
phosphamide for intermediate‐risk rhabdomyosarcoma: Children's 
Oncology Group study D9803. J Clin Oncol. 2009;27:5182‐5188. 
https ://doi.org/10.1200/JCO.2009.22.3768
 11. Pappo AS, Lyden E, Breitfeld P, et al. Two consecutive phase 
II window trials of irinotecan alone or in combination with vin-
cristine for the treatment of metastatic rhabdomyosarcoma: the 
Children's Oncology Group. J Clin Oncol. 2007;25:362‐369. https 
://doi.org/10.1200/JCO.2006.07.1720
 12. Walterhouse DO, Pappo AS, Meza JL, et al. Shorter duration 
therapy using vincristine, dactinomycin, and lower‐dose cyclo-
phosphamide with or without radiotherapy for patients with newly 
diagnosed low‐risk rhabdomyosarcoma: a report from the soft tis-
sue sarcoma committee of the children's oncology. J Clin Oncol. 
2014;32:3547‐3552. https ://doi.org/10.1200/JCO.2014.55.6787
 13. Weigel BJ, Lyden E, Anderson JR, et al. Intensive multiagent ther-
apy, including dose‐compressed cycles of ifosfamide/etoposide and 
vincristine/doxorubicin/cyclophosphamide, irinotecan, and radia-
tion, in patientswith high‐risk rhabdomyosarcoma: a report from 
the Children's Oncology Group. J Clin Oncol. 2016;34(2):117‐122. 
https ://doi.org/10.1200/JCO.2015.63.4048
 14. Hawkins DS, Anderson JR, Mascarenhas L, et al. Vincristine, 
dactinomycin, cyclophosphamide (VAC) versus VAC/V plus irino-
tecan (VI) for intermediate‐risk rhabdomyosarcoma (IRRMS): a 
report from the Children's Oncology Group soft tissue sarcoma 
committee. Proc Am Soc Clin Oncol. 2014; Abstr 10004.
 15. Joshi D, Anderson JR, Paidas C, Breneman J, Parham DM, Crist 
W. Age is an independent prognostic factor in Rabdomyosarcoma: 
a report from the soft tissue sarcoma committee of the Children's 
Oncology Group. Pediatr Blood Cancer. 2004;42:64‐73. https ://
doi.org/10.1002/pbc.10441 
 16. Maurer HM, Beltangady M, Gehan EA, et al. The intergroup rhab-
domyosarcoma study‐I a final report. Cancer. 1988;61:209‐220.
 17. Rudzinksi ER. Histology and fusion status in rhabdomyosarcoma. 
Am Soc Clin Oncol Ed B. 2013;425‐428.
 18. Chen X, Stewart E, Shelat A, et al. Targeting oxidative stress in em-
bryonal rhabdomyosarcoma. Cancer Cell. 2013;24:710‐724. https 
://doi.org/10.1016/j.ccr.2013.11.002
 19. Shern JF, Chen L, Chmielecki J, et al. Comprehensive genomic 
analysis of rhabdomyosarcoma reveals a landscape of alterations 
affecting a common genetic axis in fusion‐positive and fusion‐
negative tumors. Cancer Discov. 2014;4:216‐231. https ://doi.
org/10.1158/2159-8290.CD-13-0639
 20. Barr FG, Smith LM, Lynch JC, et al. Examination of gene fusion 
status in archival samples of alveolar rhabdomyosarcoma entered 
on the intergroup rhabdomyosarcoma study‐III trial: a report from 
the Children's Oncology Group. J Mol Diagn. 2006;8:202‐208.
 21. Nishio J, Althof PA, Bailey JM, et al. Use of a novel FISH assay 
on paraffin‐embedded tissues as an adjunct to diagnosis of alveolar 
rhabdomyosarcoma. Lab Invest. 2006;86:547‐556.
 22. Zeileis A, Hothorn T. partykit: a toolkit for recursive partytioning. 
https ://cran.r-proje ct.org/web/packa ges/party kit/vigne ttes/party kit.
pdf. Accessed July 2, 2016.
 23. Hothorn T, Hornik K, Zeileis A. Unbiased recursive partitioning: 
a conditional inference framework unbiased recursive partition-
ing: a conditional inference framework. J Comput Graph Stat. 
2006;15(3):651‐674. https ://doi.org/10.1198/10618 6006X 133933
 24. Segal RM. Regression trees for censored. Biometrics. 
1988;44(1):35‐47. https ://doi.org/10.2307/2531894
 25. Kaplan EL, Meier P. Nonparametric estimation from incomplete 
observations. J Am Stat Assoc. 1958;53(282):457‐481. https ://doi.
org/10.2307/2281868
 26. Simon RM, Subramanian J, Li M, Menezes S. Using cross‐valida-
tion to evaluate predictive accuracy of survival risk classifiers based 
on high‐dimensional data. Brief Bioinform. 2011;12(3):203‐214. 
https ://doi.org/10.1093/bib/bbr001
 27. Naranjo A, Irwin MS, Hogarty MD, Cohn SL, Park JR, London WB. 
Statistical framework in support of a revised Children's Oncology 
Group neuroblastoma risk classification system. JCO Clin Cancer 
Informatics. 2018; 2:1‐15. https ://doi.org/10.1200/CCI.17.00140 
 28. Peto R, Pike MC, Armitage P, et al. Design and analysis of random-
ized clinical trials requiring prolonged observation of each patient. 
II. Analysis and examples. Br J Cancer. 1977;35(1):1‐39. https ://
doi.org/10.1038/bjc.1977.1
 29. Hingorani P, Missiaglia E, Shipley J, et al. Clinical application 
of prognostic gene expression signature in fusion gene‐nega-
tive rhabdomyosarcoma: a report from the Children's Oncology 
Group. Clin Cancer Res. 2015;21(20):4733‐4739. https ://doi.
org/10.1158/1078-0432.CCR-14-3326
 30. Missiaglia E, Williamson D, Chisholm J, et al. PAX3/FOXO1 fusion 
gene status is the key prognostic molecular marker in rhabdomyosar-
coma and significantly improves current risk stratification. J Clin Oncol. 
2012;30(14):1670‐1677. https ://doi.org/10.1200/JCO.2011.38.5591
 31. Rudzinski ER, Anderson JR, Chi Y‐Y, et al. Histology, fusion 
status, and outcome in metastatic rhabdomyosarcoma: a report 
from the Children's Oncology Group. Pediatr Blood Cancer. 
2017;64(12):1‐7. https ://doi.org/10.1002/pbc.26645 
6448 |   HIBBITTS eT al
 32. Sumegi J, Streblow R, Frayer RW, et al. Recurrent t(2;2) and 
t(2;8) translocations in rhabdomyosarcoma without the canoni-
cal PAX‐FOXO1 fuse PAX3 to members of the nuclear receptor 
transcriptional coactivator family. Genes Chromosomes Cancer. 
2010;49(3):224‐236. https ://doi.org/10.1002/gcc.20731 
SUPPORTING INFORMATION
Additional supporting information may be found online in 
the Supporting Information section at the end of the article.  
How to cite this article: Hibbitts E, Chi Y‐Y, 
Hawkins DS, et al. Refinement of risk stratification 
for childhood rhabdomyosarcoma using FOXO1 
fusion status in addition to established clinical 
outcome predictors: A report from the Children's 
Oncology Group. Cancer Med. 2019;8:6437–6448. 
https ://doi.org/10.1002/cam4.2504
© 2019. This work is published under
http://creativecommons.org/licenses/by/4.0/(the “License”).  Notwithstanding
the ProQuest Terms and Conditions, you may use this content in accordance
with the terms of the License.
